Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-02-05
1998-11-03
Spivack, Phyllis G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31445
Patent
active
058309047
ABSTRACT:
Methods are disclosed that suggest the use of lobeline and analogs thereof in treating individuals for drug dependence and withdrawal and for eating disorders.
REFERENCES:
patent: 3901248 (1975-08-01), Lictneckert et al.
patent: 4971079 (1990-11-01), Talapin et al.
patent: 5272144 (1993-12-01), Melloni et al.
patent: 5403595 (1995-04-01), Kitchell et al.
patent: 5414005 (1995-05-01), Schneider et al.
patent: 5468755 (1995-11-01), Cincotta et al.
patent: 5486362 (1996-01-01), Kitchell et al.
patent: 5536503 (1996-07-01), Kitchell et al.
patent: 5552429 (1996-09-01), Wong et al.
patent: 5576321 (1996-11-01), Krushinski, Jr. et al.
Olin, B.R. et al., "Smoking Deterrents," In Drug Facts and Comparisons. 1995 edition, ed. by B.R. Olin et al., pp. 3087-3095, St. Louis, MO: J.B. Lippincott Co., 1995.
Sloan, J.W. et al., "The comparative binding characteristics of nicotinic ligands and their phamracology," Pharmacol. Biochem. Behav., 30:255-267 (1988).
Hamann, S.R. et al., "Hyperalgesic and analgesic actions of morphine, U50-448, naltrexone, and (-)lobeline in the rat brainstem," Pharmacol. Biochem. Behav., 47:197-201 (1994).
Brioni, J.D. et la., "Nicotinic receptor agonist exhibit anxiolytic-like effects on the elevated plus-maze test," Eur. J. Pharmacol., 238:1-8 (1993).
Decker, M.W. et al., "Effects of lobeline, a nicotinic receptor agonist, on learning and memory," Pharmacol. Biochem. Behav., 45:571-576 (1993).
Nunn-Thompson et al., "Pharmacotherapy for smoking cessation," Clin. Pharmacy., 8:710-720 (1989).
Prignot, J., "Pharmacological approach to smoking cessation," Eur. Respir. J., 2:550-560 (1989).
Kalyuzhnyy, V.V., "The treatment of nicotinism with the aid of lobeline and its influence on vegetative and vascular reactions," J. Neural. Psychiat., 68:1864-1870 (1968).
Stolerman, I.P. et al., "Dissociation between the locomotor stimulant and depressant effects of nicotinic agonists in rats," Psychopharmacol., 117:430-437 (1995).
Fudala, P.J. et al., "Further studies on nicotine-induced conditioned place preference in the rat," Pharmacol. Biochem. Behav., 25:1041-1049 (1986).
Geller, I. et al., "Effects of nicotine monomethiodide, lobeline, chlordiazepoxide, memprobamate and caffeine on a discrimination task in laboratory rats," Psychopharmacol. (Berl.), 20:355-365 (1971).
Schechter, M.D. et al., "Nicotine as a discriminative cue in rats: inability of related drugs to produce a nicotine-like cuing effect," Psychopharmacol. (Berl.), 27:379-387 (1972).
Reavill, C. et al., "Behavioral and pharmacokinetics studies on nicotine, cytosine and lobeline," Neuropharmacol., 29(7):619-624 (1990).
Romano, C. et al., "Stereospecific nicotine receptors on rat brain membranes," Science, 210:647-650 (1980).
Decker, M.W. et al., "Diversity of neuronal nicotinic actylcholine receptors: lessons from behavior and implications for CNS therapeutics," Life Sci., 56:545-570 (1995).
Yamada, S. et al., "Brain nicotinic acetylcholine receptors biochemical characterization by neosurugatoxin," Mol. Pharmacol., 28:120-127 (1985). class of high affinity sites in rat brain membrane," Mol. Pharmacol., 29:448-454 (1986).
S. Martin et al., "Opioid and nicotinic Med Llary Hyperalgesic Influences in the Decerebrated Rat"Pharmacol Biohcem and Behav.29 725-731 1988.
Broussolle, E.P. et al., "In vivo binding of .sup.3 H-nicotine in the mouse brain," Life Sci., 44:1123-1132 (1989).
Bhat, R.V. et al., "Regulation of brain nicotinic receptors by chronic agonist infusion,"J. Neurochem., 56(6):1932-1939 (1991). 242:99-106 (1982).
Takano, Y. et al., "Presynaptic modulation of the release of dopamine from striatal synaptosomes: difference in the effects of high K.sup.+ stimulation, methamphetamine and nicotinic drugs," Brain Res., 279:330-334 (1983).
Grady, S. et al., "Characterization of nicotine receptor-mediated .sup.3 H-dopamine release from synaptosomes prepared from mouse striatum," J. Neurochem., 59:848-856 (1992).
Crooks Peter A.
Dwoskin Linda P.
Spivack Phyllis G.
University of Kentucky Research Foundation
LandOfFree
Lobeline compounds as a treatment for psychostimulant abuse and does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lobeline compounds as a treatment for psychostimulant abuse and , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lobeline compounds as a treatment for psychostimulant abuse and will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-689452